Department of Immunology-IMM7, The Scripps
Research Institute, La Jolla, California
92037,1 and
Laboratory of Persistent
Viral Diseases, Rocky Mountain Laboratories, National Institute of
Allergy and Infectious Diseases, Hamilton, Montana
598402
Most individuals infected with human immunodeficiency virus type 1 (HIV-1) initially harbor macrophage-tropic, non-syncytium-inducing (M-tropic, NSI) viruses that may evolve into T-cell-tropic,
syncytium-inducing viruses (T-tropic, SI) after several years. The
reasons for the more efficient transmission of M-tropic, NSI viruses
and the slow evolution of T-tropic, SI viruses remain unclear, although
they may be linked to expression of appropriate chemokine coreceptors for virus entry. We have examined plasma viral RNA levels and the
extent of CD4+ T-cell depletion in SCID mice reconstituted
with human peripheral blood leukocytes following infection with
M-tropic, dual-tropic, or T-tropic HIV-1 isolates. The cell tropism was
found to determine the course of viremia, with M-tropic viruses
producing sustained high viral RNA levels and sparing some
CD4+ T cells, dual-tropic viruses producing a transient and
lower viral RNA spike and extremely rapid depletion of CD4+
T cells, and T-tropic viruses causing similarly lower viral RNA levels
and rapid-intermediate rates of CD4+ T-cell depletion. A
single amino acid change in the V3 region of gp120 was sufficient to
cause one isolate to switch from M-tropic to dual-tropic and acquire
the ability to rapidly deplete all CD4+ T cells.
 |
INTRODUCTION |
The envelope gene of human
immunodeficiency virus type 1 (HIV-1) determines the cell tropism of
the virus (11, 32, 47, 62), the use of chemokine receptors
as cofactors for viral entry (4, 17), and the ability of the
virus to induce syncytia in infected cells (55, 60).
Cell tropism is closely linked to but probably not exclusively
determined by the ability of different HIV-1 envelopes to bind CD4 and
the CC or the CXC chemokine receptors and initiate viral fusion with
the target cell. Macrophage-tropic (M-tropic) viruses infect primary
cultures of macrophages and CD4+ T cells and use CCR5 as
the preferred coreceptor (2, 5, 15, 23, 26, 31).
T-cell-tropic (T-tropic) viruses can infect primary cultures of
CD4+ T cells and established T-cell lines, but not primary
macrophages. T-tropic viruses use CXCR4 as a coreceptor for viral entry
(27). Dual-tropic viruses have both of these properties and
can use either CCR5 or CXCR4 (and infrequently other chemokine
receptors [25]) for viral entry (24, 37,
57). M-tropic viruses are most frequently transmitted during
primary infection of humans and persist throughout the duration of the
infection (63). Many, but not all, infected individuals show
an evolution of virus cell tropism from M-tropic to dual-tropic and
finally to T-tropic with increasing time after infection (21, 38,
57). Increases in replicative capacity of viruses from patients
with long-term infection have also been noted (22), and the
switch to the syncytium-inducing (SI) phenotype in T-tropic or
dual-tropic isolates is associated with more rapid disease progression
(10, 20, 60). Primary infection with dual-tropic or T-tropic
HIV, although infrequent, often leads to rapid disease progression
(16, 51). The viral and host factors that determine the
higher transmission rate of M-tropic HIV-1 and the slow evolution of
dual- or T-tropic variants remain to be elucidated (4).
These observations suggest that infection with T-tropic, SI virus
isolates in animal model systems with SCID mice grafted with human
lymphoid cells or tissue should lead to a rapid course of disease
(1, 8, 44-46). While some studies in SCID mice grafted with
fetal thymus and liver are in agreement with this concept (33,
34), our previous studies with the human peripheral blood leukocyte-SCID (hu-PBL-SCID) mouse model have shown that infection with M-tropic isolates (e.g., SF162) causes more rapid CD4+ T-cell depletion than infection with T-tropic, SI
isolates (e.g., SF33), despite similar proviral copy numbers, and that
this property mapped to envelope (28, 41, 43). However, the
dual-tropic 89.6 isolate (19) caused extremely rapid
CD4+ T-cell depletion in infected hu-PBL-SCID mice that was
associated with an early and transient increase in HIV-1 plasma viral
RNA (29). The relationship between cell tropism of the virus
isolate and the pattern of disease in hu-PBL-SCID mice is thus
uncertain. We have extended these studies by determining the kinetics
of HIV-1 RNA levels in serial plasma samples of hu-PBL-SCID mice infected with primary patient isolates or laboratory stocks that differ
in cell tropism and SI properties. The results showed significant differences in the kinetics of HIV-1 replication and CD4+
T-cell depletion that are determined by the cell tropism of the virus
isolate.
 |
MATERIALS AND METHODS |
Virus.
HIV-1SF2, HIV-1SF162,
HIV-1JR-FL, HIV-1JR-CSF, and
HIV-189.6 have been described previously (13, 19, 35,
36). HIV-1241 and HIV-1242 are recently
described molecular clones that differ only by a glutamine
(HIV-1241)-to-glutamic acid (HIV-1242) change at position 25 of the V3 loop (14). HIV-1241 is
dual-tropic and SI, while HIV-1242 is M-tropic and
non-syncytium inducing (NSI) (14, 58). The two virus
isolates showed similar kinetics of virus replication in activated
peripheral blood mononuclear cell (PBMC) cultures (p24 antigen levels
on days 4 and 8 of culture were as follows: for HIV-1241,
130 and 18,367 pg/ml and for HIV-1242, 90 and 9,390 pg/ml).
Primary patient isolates CS93, CD65, and MT82 are M-tropic, T-tropic,
and T-tropic, respectively (52), and were used after a
single round of in vitro expansion. hu-PBL-SCID mice were infected with
103 tissue culture infectious doses (TCID) by
intraperitoneal injection. TCID was determined by limiting dilution of
virus stocks with phytohemagglutinin and interleukin 2 (IL-2)-activated
human PBMC.
Mice.
C.B-17 scid/scid mice were bred in a
closed, specific-pathogen-free environment at The Scripps Research
Institute. Mice were screened for mouse immunoglobulin at 6 to 8 weeks
of age, and animals with >10 µg/ml were discarded as "leaky"
(9). Human PBMC were prepared by density separation from
normal adult donors who were Epstein-Barr virus seronegative and who
were demonstrated by PCR to have normal CCR5 coding regions
(52). A single normal human donor was used for each of four
experiments, and no donor was used twice. The experiment shown in Fig.
5 employed a donor who was heterozygous for the 32-bp deletion in CCR5
(48). A total of 20 × 106 cells were
injected intraperitoneally into SCID mice 2 weeks prior to virus
exposure, as described previously (28, 41). Each
experimental group consisted of 3 to 5 mice, and most virus isolates
were compared in at least two experiments.
Virus infection.
Plasma virus RNA copy number was determined
by quantitative PCR assay (Amplicor; Roche Molecular Systems,
Somerville, N.J.). Plasma samples from multiple time points of
infection were frozen and subsequently assayed at the same time to
minimize interassay variation. Virus infection of animals was confirmed
by isolation of virus in cocultures of activated human PBMC and cells
recovered from hu-PBL-SCID mice by peritoneal lavage or preparation of
cell suspensions from spleens or local lymph nodes or by amplification of proviral gag sequences by PCR (45).
Flow cytometry.
Recovery of human cells and CD4+
T-cell depletion was monitored by flow cytometry. Briefly, recovered
cells were stained with fluorescein- or phycoerythrin-labeled
monoclonal antibodies to murine H-2Kd and human CD45, CD3,
CD4, CD8, CD25, CD69, CD45RA, and CD45RO. Antibodies were obtained
either from immunocytometry systems (Becton Dickinson, Mountain View,
Calif.) or Pharmingen (San Diego, Calif.). Staining was evaluated
for a minimum of 104 cells with a FACscan (Becton
Dickinson) flow cytometer, and data were analyzed with Cellquest
(Becton Dickinson) software. Data are presented as the mean percentage
of CD4+ T cells as a fraction of total CD3+ T
cells, standardizing the result for variable recovery of total human T
cells in different sites and different animals. The ratio of
CD4+ to CD3+ T cells is reported separately for
human cells recovered by peritoneal lavage and from pooled samples of
local (mesenteric and periportal) lymph nodes. These lymph nodes have a
higher proportion of CD45RA+ T cells (see Fig. 5) and show
kinetics of CD4+ T-cell depletion that differ from those of
human cells recovered by peritoneal lavage (reference
29 and below). In HIV-1-infected mice with
CD4+ T-cell depletion, the number of CD8+ T
cells was always close to or equal to the number of CD3+ T
cells, indicating a loss of T cells and not CD4 modulation (data not
shown).
 |
RESULTS |
Selection of HIV-1 isolates differing in cell tropism.
The
cell tropism and V3 sequences of the HIV-1 isolates used in these
experiments are presented in Table 1. The
origin and V3 sequences of the primary patient isolates CS93 and CD65
have recently been reported elsewhere (52). The T-tropic
MT82 isolate was recovered from a patient with hemophilia who was
asymptomatic at the time of isolation (>10 years after infection) but
has subsequently progressed to AIDS. Each of these virus isolates
replicated well in primary cultures of PBMC or purified
CD4+ T cells, and none of the M-tropic isolates were able
to replicate in PBMC from donors homozygous for the CCR5 32-bp deletion
(reference 52 and data not shown). By contrast,
T-tropic isolates replicated well in MT-2 cells and PBMC from
CCR5-negative donors (52).
Kinetics of plasma viremia following HIV-1 infection.
Each
HIV-1 isolate was used to infect multiple hu-PBL-SCID mice in one or
more of four replicate experiments, depicted in Fig. 1 through 4.
Weekly samples of plasma were used for the determination of viral RNA
copy number, and results are presented for individual animals over the
duration of each experiment. In experiments 1 and 4, the number of
human CD4+ T cells was also determined and compared to that
in uninfected control animals. In the experiment shown in Fig.
1, we infected mice with one of two
T-tropic isolates, SF2 or CD65, or one of two M-tropic isolates, SF162
or CS93. Infection with T-tropic isolates leads to transient viral RNA
expression between 1 and 4 weeks after infection, and few or no
residual CD4+ T cells were detectable by 7 to 8 weeks after
HIV-1 infection. By contrast, most mice infected with M-tropic viruses
showed increasing levels of viral RNA for up to 6 weeks after
infection, and residual CD4+ T cells were detected in all
mice with high viral RNA levels, whereas declining viral loads were
associated with reduced numbers of CD4+ T cells. The two
hu-PBL-SCID mice with the highest viral RNA copy numbers after
infection with HIV-1SF162 died before the termination of
the experiment. A second, similar experiment with the M/T-tropic 89.6 isolate as well as the T-tropic CD65 and the M-tropic CS93 HIV-1
isolates is shown in Fig. 2 (A through C,
individual mice; D, group means). Infection with 89.6 resulted in a
burst of viral RNA detected at 1 week after infection, followed by a
decline to undetectable levels by 2 weeks, when depletion of
CD4+ T cells is complete (29). Infection with
the T-tropic CD65 isolate resulted in a peak of plasma viral RNA at 1 or 2 weeks after infection, with a subsequent decline to the limit of
detection by 3 to 5 weeks after infection. As observed previously (Fig. 1), infection with the M-tropic CS93 isolate caused a progressive increase in viral RNA levels to a mean value of >106
copies/ml. In the experiment shown in Fig.
3, the studies with 89.6 and SF2 were
repeated and the T-tropic MT82 isolate and the M-tropic JR-FL isolate
were added. Both the dual-tropic 89.6 and the T-tropic MT82 isolates
produced peaks of plasma viral RNA at 1 week after infection, with
rapid declines to baseline levels thereafter. Infection with T-tropic
SF2 led to a later peak in plasma viral RNA levels, followed by a
decline to baseline levels by 4 weeks after infection, when most
CD4+ T cells have been depleted (41). Infection
with the M-tropic JR-FL isolate led to a more sustained high level of
virus replication that was still high in all mice after 4 weeks of
infection. In the last of the four experiments (Fig.
4), the M-tropic 242 isolate, the
M/T-tropic 241 isolate, and the M-tropic JR-CSF isolate were compared.
As noted above, 242 and 241 differ in only a single amino acid
(14, 58). Human CD4+ T-cell survival was
measured at 2 and 4 weeks after infection in this experiment. Infection
of hu-PBL-SCID mice with the dual-tropic 241 isolate caused a burst of
virus production at 1 week after infection and depleted all human
CD4+ T cells by 2 weeks after infection, a pattern similar
to that seen with 89.6 infection. By contrast, infection with the
M-tropic 242 isolate caused a sustained increase in viral RNA levels
and caused minimal depletion of CD4+ T cells at either 2 and 4 weeks after infection in human cells recovered by peritoneal
lavage (Fig. 4D) or from local lymph nodes (Fig. 4E). The single amino
acid change that alters coreceptor usage and cell tropism also alters
the kinetics of virus replication and CD4+ T-cell
depletion. Infection with the M-tropic JR-CSF isolate caused lower but
sustained and increasing levels of viral RNA and substantial depletion
of CD4+ T cells by 4 weeks after infection.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Plasma HIV RNA copy number in hu-PBL-SCID mice infected
with the T-tropic HIV-1 isolate SF2 (A), the M-tropic isolate SF162
(B), the primary T-tropic patient isolate CD65 (C), or the primary
M-tropic isolate CS93 (D). Each line represents serial measurements on
an individual hu-PBL-SCID mouse from 1 to 6 weeks after infection. (E)
Percentage of remaining CD4+ T cells in the peritoneal
cavity (compared to total human CD3+ T cells) at 7 to 8 weeks after infection. This number was determined for individual mice
(symbol above each column matches symbol for each animal in panels A
through D) and compared to the mean (± standard error [SE])
for four uninfected hu-PBL-SCID mice (open column with error
bar). All hu-PBL-SCID mice were derived from a single human donor who
was Epstein-Barr virus seronegative and homozygous wild type at the
CCR5 locus. The detection limit of RNA copy number was 800 in this
experiment, so samples with undetectable viral RNA were assigned a
value of 800. Serial samples from individual mice were saved and
compared in the same Roche HIV Monitor Amplicor assay plate, and the
available volume of mouse plasma determined the cut-off value for HIV
RNA detection.
|
|

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 2.
Plasma HIV RNA copy number in hu-PBL-SCID mice
reconstituted with cells from another human donor (also EBV negative,
CCR5 wild-type homozygous) and infected with the dual-tropic 89.6 HIV-1
isolate (A), the primary T-tropic isolate CD65 (B), or the primary
M-tropic isolate CS93 (C). Panels A through C show the viral RNA levels
in individual hu-PBL-SCID mice, and panel D shows the mean ± SE
of each group of mice over the 5-week duration of the experiment. The
limit of detection in this experiment was 200 copies/ml, and samples
with no detectable viral RNA were assigned this value.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 3.
Plasma HIV RNA copy number in hu-PBL-SCID mice
reconstituted with cells from a third human donor (also EBV negative,
CCR5 wild-type homozygous) and infected with the dual-tropic 89.6 isolate (A), the T-tropic SF2 isolate (B), the T-tropic primary patient
isolate MT82 (C), or the M-tropic JR-FL isolate (D). The limit of
detection in this experiment was 400 copies/ml, and samples with no
detectable viral RNA were assigned this value.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 4.
Plasma HIV RNA copy number and percentage of
CD4+ T cells in hu-PBL-SCID mice generated from a single
human donor. Five hu-PBL-SCID mice were infected either with
HIV-1241, a dual-tropic, SI virus (A), or
HIV-1242, an M-tropic, NSI virus that differs only by a
glutamine-to-glutamic acid change in position 25 of the V3 loop
(14) (B). An additional group of five mice was infected with
the M-tropic JR-CSF isolate (C). Three mice in each group were used
for determination of CD4+ T-cell levels at 2 weeks after infection, and the remaining two mice were examined after 4 weeks of infection. (D) Percentages ± SE of CD4+ T
cells (of total human CD3+ T cells) recovered by peritoneal
lavage of the animals compared to mean values for four uninfected
control mice. Only one hu-PBL-SCID mouse infected with
HIV-1242 was available at week 4, because the mouse with
>107 HIV RNA copies/ml at week 3 after infection died.
CD4+ T cells were also enumerated in regional lymph nodes
(panel E) pooled from three mice (2 weeks after infection) or two mice
(4 weeks after infection). Since these samples were pooled, no SE is
shown.
|
|
We performed a similar experiment with HIV-1242 and
HIV-1241 in hu-PBL-SCID mice derived from a CCR5
32/+ heterozygous donor, since previous experiments had shown
delayed kinetics of M-tropic virus replication in such mice
(52). The results (Fig. 5A)
show a difference in the kinetics of plasma virus RNA levels similar to
that observed in the experiment shown in Fig. 4, with
HIV-1241 producing a more transient viremia than
HIV-1242. Infection with 241 caused a profound decline in
CD4+ T cells in both peritoneal cells and lymph nodes by 2 weeks after infection, whereas mice infected with 242 showed no decline
in CD4+ T cells at this time (Fig. 5B). The reduction in
CCR5 expression in this
32/+ heterozygous donor does not impact the
distinct kinetics of replication and CD4+ T-cell depletion
caused by the amino acid change between 242 and 241.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
Plasma HIV RNA copy number and recovery of
CD4+ T cells in hu-PBL-SCID mice generated from a single
donor who is heterozygous for the CCR5 32 mutation. Five hu-PBL-SCID
mice were infected with either HIV-1241 or
HIV-1242 (as in the experiment shown in Fig. 4). The
geometric mean RNA copy number (± relative SE) for each group of mice
is shown for 1 to 3 weeks after infection (A). Three mice from each
group were used to determine the extent of CD4+ T-cell
depletion at 2 weeks after infection (B). Samples of peritoneal lavage
cells (PC) were assayed from individual mice, and the mean ± SE
is shown. Samples from lymph nodes (LN) were pooled prior to analysis,
so no SE is displayed.
|
|
Potential sites of HIV-1 replication.
These results imply that
infection with M-tropic virus may cause sustained viremia because of
slower depletion of CD4+ T cells, but our earlier data
suggested that M-tropic viruses caused more rapid CD4+
T-cell depletion than T-tropic viruses (28, 41). We repeated these earlier experiments with the M-tropic isolate SF162 and the
T-tropic isolate SF2, but we evaluated survival of human
CD4+ T cells in both peritoneal lavage cells (as before)
and human cells recovered from lymph nodes draining the peritoneal
cavity. The percentage of surviving human CD4+ T cells at 2 weeks after infection is shown in Fig.
6A. Although infection with SF162 caused
a greater depletion of CD4+ T cells in the population of
human cells recovered from the peritoneal cavity, in agreement with our
earlier results, infection with SF2 caused a significantly
(P < 0.05) greater depletion of human CD4+
T cells in the local lymph nodes. It is thus possible that the human
cells in these lymph nodes are the source of continued virus replication following infection with M-tropic but not T-tropic or
dual-tropic isolates. We analyzed the composition of human cells
recovered from the two sites, peritoneal cavity and local lymph nodes,
of uninfected hu-PBL-SCID mice by two-color flow cytometry (Fig. 6B and
C). While CD3+ T cells represented >90% of recovered
human cells (CD45+) in both sites, the lymph nodes
had a higher percentage of CD4+ T cells and
one-third of CD4+ T cells had the naive CD45RA+
phenotype. By contrast, over 90% of human CD4+ T cells
recovered from the peritoneal cavity had the activated/memory CD45RO+ phenotype (6), and a higher percentage
also expressed the CD25 IL-2 receptor, indicating recent
activation. These results suggest that human CD4+ T
cells are more activated and/or selected for memory cells in the
peritoneal cavities of hu-PBL-SCID mice than in repopulated lymph
nodes.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 6.
(A) Recovery of human CD4+ T cells from
peritoneal lavage cells (filled bars) or local lymph nodes (hatched
bars) of hu-PBL-SCID mice infected 2 weeks earlier with either
HIV-1SF2 or HIV-1SF162. The numbers represent
the mean ± SE of individual determinations on 4 to 5 mice per
group and are expressed as a percentage of recovered total human T
cells (CD3+). CD3+ T cells represented
>90% of recovered human cells. Human cells represented 79 to 88% of
all cells recovered from the peritoneal lavage of uninfected
hu-PBL-SCID mice and from 37 to 89% of cells recovered from local
lymph nodes. The numbers of recovered human cells declined in
parallel with the loss of CD4+ T cells after HIV-1
infection in both sites. (B) Phenotype of human cells recovered from
the peritoneal cavity of control, uninfected hu-PBL-SCID mice.
Two-color immunofluorescence staining of cells was performed to
identify memory/activated CD4 T cells, which express CD45RO, CD25
(IL-2R alpha chain), and/or CD69. (C) Phenotype of human cells
recovered from the local lymph nodes draining the peritoneal cavity of
hu-PBL-SCID mice and stained as in panel B.
|
|
 |
DISCUSSION |
These results show that HIV-1 isolates which differ in cell
tropism and coreceptor usage give two distinct patterns of virus replication and CD4+ T-cell depletion in the hu-PBL-SCID
model. Infection with the M-tropic isolates SF162, JR-CSF, JR-FL, 242, and CS93 resulted in high and increasing levels of plasma virus RNA
over the first 4 to 6 weeks of infection, and peak levels of viral RNA
often exceeded 106 copies/ml (Table
2). Residual human CD4+ T
cells were usually present in hu-PBL-SCID mice infected with M-tropic
HIV-1, particularly in the lymph nodes of reconstituted mice (Fig. 6)
and in those mice with the highest viremia (Fig. 1). Declining levels
of viral RNA correlated with a complete or near complete loss of
CD4+ T cells (e.g., Fig. 1D and E). Within the group of
M-tropic isolates, infection with SF162 and 242 caused more rapid
increases in viral RNA levels and infection with JR-CSF resulted in
slower increases (e.g., Fig. 4B versus C), but these differences did
not obscure the general pattern of plasma viremia associated with
M-tropic viruses. The peak levels of viral RNA differed between HIV
isolates (Table 2) but were generally higher than those attained
following infection with M/T- or T-tropic isolates and peaked later.
Infection of hu-PBL-SCID mice with M/T- or T-tropic HIV-1 isolates led
to a distinctive and shared pattern of viral replication and
CD4+ T-cell depletion. Infection with the dual-tropic
isolates 89.6 and 241 led to a peak level of viral RNA at 1 week after
infection, and no viral RNA was detectable at 2 or more weeks after
infection in most animals (Fig. 2 through 5). Infection with M/T-tropic isolates caused the loss of nearly all CD4+ T cells in both
the peritoneal cavity and lymph nodes of infected mice within 2 weeks
(Fig. 4 and 5), and the failure to continue virus replication is
probably explained by the elimination of all CD4+ target
cells for infection. The peak levels of viral RNA ranged from
104 to 105 copies/ml following infection with
M/T-tropic isolates (Table 2). Infection of hu-PBL-SCID mice with the
T-tropic isolates SF2 and CD65 caused a pattern of plasma viremia
intermediate between those of M-tropic and M/T-tropic viruses (Fig. 1
through 3), but infection with the T-tropic primary isolate MT82 caused
an earlier and more transient peak of viremia, similar to the pattern
seen with M/T-tropic isolates (Fig. 3). Peak levels of viral RNA were observed between 1 and 3 weeks after infection, and levels tended to
decline to undetectable by 4 weeks after infection. Peak viral loads
varied from 103 to nearly 106 copies/ml, with
the mean peak values being close to 105 copies/ml (Table
2), a level intermediate between the higher values seen with M-tropic
virus infection and the lower values seen with M/T-tropic virus
infection, although there was considerable overlap in peak viral RNA
levels between individual mice infected with either M/T- or T-tropic
isolates.
The levels of plasma viral RNA attained 1 week after infection
presumably reflect the efficiency of virus transmission (in this case,
the result of intraperitoneal injection of 103 TCID of
cell-free infectious virus) and of the initial rounds of virus
replication. We have not observed the onset of CD4+ T-cell
depletion prior to day 9 postinfection in any of a large series of
experiments with these HIV-1 isolates. Although some hu-PBL-SCID mice
infected with M-tropic isolates showed very high viral RNA levels by 1 week after infection, there was no consistent significant difference in
the transmission of virus isolates that segregated with cell tropism
(e.g., Fig. 2D). This result suggests that M-tropic viruses have only a
small advantage in transmission in this animal model. However, all
hu-PBL-SCID mice challenged with M- or M/T-tropic viruses are
consistently infected, whereas occasional mice challenged with T-tropic
isolates fail to become infected, in agreement with the results of one
recent study (39). Another study (59) indicates
that SCID-hu mice transplanted with human fetal thymus and
liver are more easily infected with M-tropic variants of HXSB-2 than
with the parental T-tropic isolate. These studies and our observations
support a possible transmission advantage for M-tropic HIV-1 isolates
that was not particularly evident in the present series of experiments.
The most striking correlation seen in this series of experiments was
that between the levels and duration of plasma viremia and the rate of
CD4+ T-cell depletion. Viremia was low and transient in
hu-PBL-SCID mice infected with M/T-tropic isolates when the pace of
CD4+ T-cell depletion is most rapid. Viremia was somewhat
higher and more persistent following infection with two of three
T-tropic isolates, resulting in intermediate rates of CD4+
T-cell depletion, although the rate seemed to vary between human T
cells in the peritoneal cavity (Fig. 6A, slower, and references 28 and 41) and those found in
local lymph nodes (Fig. 6A, faster). Finally, viremia was sustained at
high levels following infection with M-tropic isolates, resulting in
slower rates of CD4+ T-cell depletion, particularly in the
lymph nodes repopulated with both naive and memory CD4+ T
cells (Fig. 6). This interpretation is in general agreement with the
many observations that primary M-tropic HIV-1 isolates are less
cytopathic and often show lower replication rates than M/T- or T-tropic
isolates from late-stage patients (12, 20, 34, 56, 60, 61)
and differs from our interpretation of earlier studies that suggested
M-tropic HIV-1 isolates were more pathogenic than T-tropic isolates in
the hu-PBL-SCID model (41, 42). These data also suggest that
the switch from M-tropic to M/T-tropic HIV-1 may be more important for
increasing the rate of CD4+ T-cell loss than the switch to
a T-tropic variant (20, 21, 64). The increased rate of
CD4+ T-cell depletion caused by the single amino acid
change between HIV-1242 and HIV-1241 was
particularly striking (Fig. 4 and 5). These two viruses show little
difference in replication rate (see Materials and Methods), so the
change in cell tropism and coreceptor usage appears to be the major
explanation for the enhanced pathogenicity.
One of the T-tropic, SI isolates we have studied previously was SF33
(41); infection with SF33 appears to cause a more persistent infection, with lower levels of plasma viremia, than infection with
other T-tropic isolates studied (data not shown). More extensive analysis of infection with this isolate is under way, but the delayed
CD4+ T-cell depletion caused by SF33 infection seems to be
isolate specific.
Recent work (7) has shown that CXCR4 is expressed primarily
on naive CD4+ T cells and that CCR5 is expressed mainly on
memory T cells. This observation may explain the different kinetics of
CD4+ T-cell depletion following infection with M- or
T-tropic HIV-1 in the two major sites of human cell reconstitution in
hu-PBL-SCID mice (Fig. 6). The fraction of naive CD45RA+
CD4+ T cells in the lymph nodes of the mice would be
resistant to M-tropic virus infection because of low expression of the
CCR5 coreceptor, yet susceptible to T-tropic virus infection because of
higher expression of the CXCR4 coreceptor. Almost all of the human
CD4+ T cells recovered from the peritoneal cavity are of
the memory or activated phenotype (Fig. 6) and thus may express less
CXCR4 and more CCR5. Infection with M-tropic HIV-1 isolates may
progress faster in this compartment and result in the earlier loss of
CD4+ T cells (Fig. 6 and references 28
and 41). The sustained high viral RNA levels seen
following infection with M-tropic isolates would be predicted to result
from a more persistent infection in the lymph nodes of hu-PBL-SCID mice
which might be due to an ongoing conversion of naive T cells to an
activated phenotype. Some of these cells may migrate to the peritoneal
cavity, providing a source of new CD4+ T cells to replace
those previously depleted by infection. Alternatively, CD4+
T cells infected with M-tropic HIV-1 may produce progeny virions for
substantially longer than T cells infected with M/T- or T-tropic virus.
The additional target cells available to M- and M/T-tropic virus, in
this case monocyte-derived macrophages, could also contribute to the
sustained virus production following infection with the M-tropic
isolates. However, M/T-tropic viruses appear to be unable to establish
persistent infection in macrophages or lead to macrophage destruction
in this animal model, since no plasma viremia can be detected at 2 or
more weeks after infection. Alternatively, infection of a very small
number of macrophages may not result in detectable plasma viral RNA.
It is striking that a single amino acid substitution that alters
coreceptor usage (58) and syncytium-inducing properties (14) has such a profound effect on viral replication and
CD4+ T-cell depletion in this animal model for HIV-1
infection. The predominance of M-tropic isolates throughout most of the
course of natural infection with HIV-1 suggests that there must be
selective factors promoting the maintenance of the M-tropic phenotype,
since the high mutation rate of the virus (18) and the small
number of amino acid changes necessary to change cell tropism would
otherwise allow rapid evolution of M/T- and T-tropic variants. Our
results provide one potential explanation for the predominance of
M-tropic HIV-1 if viral RNA levels observed during the relatively short course of infection in the hu-PBL-SCID mice can be extrapolated to
infectious virions recovered from chronically infected humans. If an
individual were infected with a mixture of M-tropic and M/T-tropic
viruses, our results suggest that most of the plasma viremia would be
contributed by the M-tropic virus. This effect would result from the
longer duration of virus production by individual CD4+ T
cells infected with M-tropic viruses compared to CD4+ T
cells infected with the more rapidly cytopathic dual-tropic virus. The
switch to dual tropism, or acquisition of the ability to use CXCR4 as a
coreceptor, would not compensate for this effect, since few naive
CD4+ T cells would be present as new targets for infection
(3, 53). It is thus possible that many M/T-tropic variants
arise transiently, are unable to displace the predominant M-tropic
virus population, and disappear due to destruction of their target
population, without detection in the plasma virus pool. The acquisition
of the SI phenotype may also serve to isolate M/T-tropic virus in localized foci of infected cells (40, 54) and limit systemic spread of the virus. It should also be noted that differential half-lives of cells infected with HIV-1 differing in cell tropism would
affect current calculations of viral and cell turnover (30, 49,
50).
We thank Andrew Beernink, Matthew Kohls, and Rebecca Sabbe for
skilled technical assistance.
This work was supported by NIH grant AI-29182 to D.E.M.
| 1.
|
Aldrovandi, G.,
G. Feuer,
L. Gao,
B. Jamieson,
M. Kristeva,
I. Chen, and J. Zack.
1993.
The SCID-hu mouse as a model for HIV-1 infection.
Nature
363:732-736[Medline].
|
| 2.
|
Alkhatib, G.,
C. Combadiere,
C. Broder,
Y. Feng,
P. Kennedy,
P. Murphy, and E. Berger.
1996.
CC CKR5: a RANTES, MIP-1 , MIP-1 receptor as a fusion cofactor for macrophage-tropic HIV-1.
Science
272:1955-1958[Abstract].
|
| 3.
|
Autran, B.,
G. Carcelain,
T. Li,
C. Blanc,
D. Mathez,
R. Tubiana,
C. Katlama,
P. Debre, and J. Leibowitch.
1997.
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
Science
277:112-116[Abstract/Free Full Text].
|
| 4.
|
Berger, E.
1997.
HIV entry and tropism: the chemokine receptor connection.
AIDS
11(A):S3-S16.
|
| 5.
|
Berson, J. F.,
D. Long,
B. J. Doranz,
J. Rucker,
F. R. Jirik, and R. W. Doms.
1996.
A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.
J. Virol.
70:6288-6295[Abstract].
|
| 6.
|
Beverley, P.
1991.
Immunological memory in T cells.
Curr. Opin. Immunol.
3:355-360[Medline].
|
| 7.
|
Bleul, C.,
L. Wu,
J. Hoxie,
T. Springer, and C. MacKay.
1997.
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.
Proc. Natl. Acad. Sci. USA
94:1925-1930[Abstract/Free Full Text].
|
| 8.
|
Bonyadi, M.,
L. Rabin,
S. Salimi,
D. Brown,
J. Kosek,
J. McCune, and H. Kaneshima.
1993.
HIV induces thymus depletion in vivo.
Nature
363:728-732[Medline].
|
| 9.
|
Bosma, G. C.,
M. Fried,
R. R. Custer,
A. Carroll,
D. M. Gibson, and M. J. Bosma.
1988.
Evidence of functional lymphocytes in some (leaky) SCID mice.
J. Exp. Med.
167:1016[Abstract/Free Full Text].
|
| 10.
|
Bozzette, S.,
J. McCutchan,
S. Spector,
B. Wright, and D. Richman.
1993.
A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus.
J. Infect. Dis.
168:1374-1379[Medline].
|
| 11.
|
Cheng-Mayer, C.,
M. Quiroga,
J. W. Tung,
D. Dina, and J. A. Levy.
1990.
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation.
J. Virol.
64:4390-4398[Abstract/Free Full Text].
|
| 12.
|
Cheng-Mayer, C.,
D. Seto,
M. Tateno, and J. A. Levy.
1988.
Biologic features of HIV-1 that correlate with virulence in the host.
Science
240:80-82[Abstract/Free Full Text].
|
| 13.
|
Cheng-Mayer, C.,
C. Weiss,
D. Seto, and J. A. Levy.
1989.
Isolates of human immunodeficiency virus type 1 from the brain may constitute a special subgroup of the AIDS virus.
Proc. Natl. Acad. Sci. USA
86:8575-8579[Abstract/Free Full Text].
|
| 14.
|
Chesebro, B.,
K. Wehrly,
J. Nishio, and S. Perryman.
1996.
Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytial formation in lymphocytes.
J. Virol.
70:9055-9059[Abstract].
|
| 15.
|
Choe, H.,
M. Farzan,
Y. Sun,
N. Sullivan,
B. Rollins,
P. Ponath,
L. Wu,
C. Mackay,
G. LaRosa,
W. Newman,
N. Gerard,
C. Gerard, and J. Sodroski.
1996.
The -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
Cell
85:1135-1148[Medline].
|
| 16.
|
Clark, S. J.,
M. S. Saag,
W. D. Decker,
S. Campbell-Hill,
J. L. Roberson,
P. J. Veldkamp,
J. C. Kappes,
B. H. Hahn, and G. M. Shaw.
1991.
High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.
N. Engl. J. Med.
324:954-960[Abstract].
|
| 17.
|
Cocchi, F.,
A. DeVico,
A. Garzino-Demo,
A. Cara,
R. Gallo, and P. Lusso.
1996.
The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection.
Nat. Med.
2:1244-1247[Medline].
|
| 18.
|
Coffin, J.
1995.
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.
Science
267:483-489.
|
| 19.
|
Collman, R.,
J. W. Balliet,
S. A. Gregory,
H. Friedman,
D. L. Kolson,
N. Nathanson, and A. Srinivasan.
1992.
An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.
J. Virol.
66:7517-7521[Abstract/Free Full Text].
|
| 20.
|
Connor, R. I.,
H. Mohri,
Y. Cao, and D. D. Ho.
1993.
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.
J. Virol.
67:1772-1777[Abstract/Free Full Text].
|
| 21.
|
Connor, R.,
K. Sheridan,
D. Ceradini,
S. Choe, and N. Landau.
1997.
Change in coreceptor use correlates with disease progression in HIV-1-infected individuals.
J. Exp. Med.
185:621-628[Abstract/Free Full Text].
|
| 22.
|
Connor, R. I., and D. D. Ho.
1994.
Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression.
J. Virol.
68:4400-4408[Abstract/Free Full Text].
|
| 23.
|
Deng, H.,
R. Liu,
W. Ellmeier,
S. Choe,
D. Unutmaz,
M. Burkhart,
P. Di Marzio,
S. Marmon,
R. Sutton,
C. Hill,
C. Davis,
S. Peiper,
T. Schall,
D. Littman, and N. Landau.
1996.
Identification of a major co-receptor for primary isolates of HIV-1.
Nature
381:661-666[Medline].
|
| 24.
|
Deng, H.,
D. Unutmaz,
V. Kewealramani, and D. Littman.
1997.
Expression cloning of new receptors used by simian and human immunodeficiency viruses.
Nature
388:296-300[Medline].
|
| 25.
|
Doranz, B.,
J. Rucker,
Y. Yi,
R. Smyth,
M. Samson,
S. Peiper,
M. Parmentier,
R. Collman, and R. Doms.
1996.
A dual-tropic primary HIV-1 isolate that uses fusin and the -chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors.
Cell
85:1149-1158[Medline].
|
| 26.
|
Dragic, T.,
V. Litwin,
G. Allaway,
S. Martin,
Y. Huang,
K. Nagashima,
C. Cayanan,
P. Maddon,
R. Koup,
J. Moore, and W. Paxton.
1996.
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
Nature
381:667-673[Medline].
|
| 27.
|
Feng, Y.,
C. Broder,
P. Kennedy, and E. Berger.
1996.
HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane, G-protein coupled receptor.
Science
272:873-877.
|
| 28.
|
Gulizia, R.,
J. Levy, and D. Mosier.
1996.
The envelope gp120 gene of human immunodeficiency virus type 1 determines the rate of CD4-positive T cell depletion in SCID mice engrafted with human peripheral blood leukocytes.
J. Virol.
70:4184-4187[Abstract].
|
| 29.
|
Gulizia, R. J.,
R. G. Collman,
J. A. Levy,
D. Trono, and D. E. Mosier.
1997.
Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice.
J. Virol.
71:4161-4164[Abstract].
|
| 30.
|
Ho, D.,
A. Neumann,
A. Perelson,
W. Chen,
J. Leonard, and M. Markowitz.
1995.
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
Nature
373:123-126[Medline].
|
| 31.
|
Huang, Y.,
W. Paxton,
S. Wolinsky,
A. Neumann,
L. Zhang,
T. He,
S. Kang,
D. Ceradini,
Z. Jin,
K. Yazdandakhsh,
K. Kunstman,
D. Erickson,
E. Dragon,
N. Landau,
J. Phair,
D. Ho, and R. Koup.
1996.
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.
Nat. Med.
2:1240-1243[Medline].
|
| 32.
|
Hwang, S. S.,
T. J. Boyle,
H. K. Lyerly, and B. Cullen.
1991.
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.
Science
253:71-74[Abstract/Free Full Text].
|
| 33.
|
Jamieson, B. D.,
G. M. Aldrovandi, and J. A. Zack.
1996.
The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS.
Semin. Immunol.
8:215-221[Medline].
|
| 34.
|
Kaneshima, H.,
L. Su,
M. L. Bonyhadi,
R. I. Connor,
D. D. Ho, and J. M. McCune.
1994.
Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse.
J. Virol.
68:8188-8192[Abstract/Free Full Text].
|
| 35.
|
Koyanagi, Y.,
S. Miles,
R. T. Mitsuyasu,
J. E. Merrill,
H. V. Vinters, and I. S. Y. Chen.
1987.
Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.
Science
236:819-822[Abstract/Free Full Text].
|
| 36.
|
Levy, J.,
A. Hoffman,
S. Kramer,
J. Landis,
J. Shimabukuro, and L. Oshiro.
1984.
Isolation of lymphocytotropic retroviruses from San Francisco patients with AIDS.
Science
225:840-842[Abstract/Free Full Text].
|
| 37.
|
Liao, F.,
G. Alkhatib,
K. Peden,
G. Sharma,
E. Berger, and J. Farber.
1997.
STRL33, a novel cytokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.
J. Exp. Med.
185:2015-2023[Abstract/Free Full Text].
|
| 38.
|
Lu, Z.-H.,
J. Berson,
Y.-H. Chen,
J. Turner,
T.-Y. Zhang,
M. Sharron,
M. Jenks,
Z.-X. Wang,
J. Kim,
J. Rucker,
J. Hoxie,
S. Peiper, and R. Doms.
1997.
Evolution of HIV-1 co-receptor usage through interactions with distinct CCR5 and CXCR4 domains.
Proc. Natl. Acad. Sci. USA
94:6426-6431[Abstract/Free Full Text].
|
| 39.
|
Markham, R.,
D. Schwartz,
A. Templeton,
J. Margolick,
H. Farzadegan,
D. Vlahov, and X.-F. Yu.
1996.
Selective transmission of HIV-1 variants to SCID mice reconstituted with human peripheral blood mononuclear cells.
J. Virol.
70:6947-6954[Abstract/Free Full Text].
|
| 40.
|
Martins, L. P.,
N. Chenciner,
B. Åsjö,
A. Meyerhans, and S. Wain-Hobson.
1991.
Independent fluctuation of human immunodeficiency virus type 1 rev and gp41 quasispecies in vivo.
J. Virol.
65:4502-4507[Abstract/Free Full Text].
|
| 41.
|
Mosier, D.,
R. Gulizia,
P. MacIsaac,
B. Torbett, and J. Levy.
1993.
Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates.
Science
260:689-692[Abstract/Free Full Text].
|
| 42.
|
Mosier, D., and H. Sieburg.
1994.
Macrophage-tropic HIV: critical for AIDS pathogenesis?
Immunol. Today
15:332-339[Medline].
|
| 43.
|
Mosier, D. E.
1996.
Human immunodeficiency virus infection of human cells transplanted to severe combined immunodeficient mice.
Adv. Immunol.
63:79-125[Medline].
|
| 44.
|
Mosier, D. E.,
R. J. Gulizia,
S. M. Baird, and D. B. Wilson.
1988.
Transfer of a functional human immune system to mice with severe combined immunodeficiency.
Nature
335:256-259[Medline].
|
| 45.
|
Mosier, D. E.,
R. J. Gulizia,
S. M. Baird,
D. B. Wilson,
D. H. Spector, and S. A. Spector.
1991.
Human immunodeficiency virus infection of human-PBL-SCID mice.
Science
251:791-794[Abstract/Free Full Text].
|
| 46.
|
Namikawa, R.,
H. Kaneshima,
M. Lieberman,
I. L. Weissman, and J. M. McCune.
1988.
Infection of the SCID-hu mouse by HIV-1.
Science
242:1684-1686[Abstract/Free Full Text].
|
| 47.
|
O'Brien, W. A.,
Y. Koyanagi,
A. Namazie,
J.-Q. Zhao,
A. Diagne,
K. Idler,
J. A. Zack, and I. S. Y. Chen.
1990.
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain.
Nature
348:69-73[Medline].
|
| 48.
|
Paxton, W. A.,
S. R. Martin,
D. Tse,
T. R. O'Brien,
J. Skurnick,
N. L. VanDevanter,
N. Padian,
J. F. Braun,
D. P. Kotler,
S. M. Wolinsky, and R. A. Koup.
1996.
Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure.
Nat. Med.
2:412-417[Medline].
|
| 49.
|
Perelson, A.,
P. Essunger,
Y. Cao,
M. Vesanen,
A. Hurley,
K. Saksela,
M. Markowitz, and D. Ho.
1997.
Decay characteristics of HIV-1-infected compartments during combination therapy.
Nature
387:188-191[Medline].
|
| 50.
|
Perelson, A.,
A. Neumann,
M. Markowitz,
J. Leonard, and D. Ho.
1996.
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
Science
271:1582-1586[Abstract].
|
| 51.
|
Piatak, M., Jr.,
L. C. Yang,
K. C. Luk,
J. D. Lifson,
M. S. Saag,
S. J. Clark,
J. C. Kappes,
B. H. Hahn, and G. M. Shaw.
1993.
Viral dynamics in primary HIV-1 infection.
Lancet
341:1099. (Letter.)
|
| 52.
|
Picchio, G. R.,
R. J. Gulizia, and D. E. Mosier.
1997.
Chemokine receptor CCR5 genotype influences the kinetics of human immunodeficiency virus type 1 infection in human PBL-SCID mice.
J. Virol.
71:7124-7127[Abstract].
|
| 53.
|
Roederer, M.,
P. Raju,
D. Mitra,
L. Herzenberg, and L. Herzenberg.
1997.
HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28.
J. Clin. Invest.
99:1555-1564[Medline].
|
| 54.
|
Sato, H.,
J. Orenstein,
D. Dimitrov, and M. Martin.
1992.
Cell-to-cell spread of HIV-1 occurs within minutes and may not involve participation of virus particles.
Virology
186:712-724[Medline].
|
| 55.
|
Schuitemaker, H.,
N. A. Kootstra,
R. E. de Goede,
F. de Wolf,
F. Miedema, and M. Tersmette.
1991.
Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture.
J. Virol.
65:356-363[Abstract/Free Full Text].
|
| 56.
|
Schuitemaker, H.,
N. A. Kootstra,
M. Groenink,
R. E. De Goede,
F. Miedema, and M. Tersmette.
1992.
Differential tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines.
AIDS Res. Hum. Retroviruses
8:1679-1682[Medline].
|
| 57.
|
Simmons, G.,
D. Wilkinson,
J. D. Reeves,
M. T. Dittmar,
S. Beddows,
J. Weber,
G. Carnegie,
U. Desselberger,
P. W. Gray,
R. A. Weiss, and P. R. Clapham.
1996.
Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.
J. Virol.
70:8355-8360[Abstract].
|
| 58.
|
Speck, R.,
K. Wehrly,
E. Platt,
R. Atchison,
I. Charo,
D. Kabat,
B. Chesebro, and M. Goldsmith.
1997.
Selective employment of chemokine receptors as HIV-1 coreceptors determined by individual amino acids within the envelope V3 loop.
J. Virol.
71:7136-7139[Abstract].
|
| 59.
|
Su, L.,
H. Kaneshima,
M. Bonyhadi,
R. Lee,
J. Auten,
A. Wolf,
B. Du,
L. Rabin,
B. Hahn,
E. Terwilliger, and J. McCune.
1997.
Identification of HIV-1 determinants for replication in vivo.
Virology
227:45-52[Medline].
|
| 60.
|
Tersmette, M.,
R. E. de Goede,
B. J. Al,
I. N. Winkel,
R. A. Gruters,
H. T. Cuypers,
H. G. Huisman, and F. Miedema.
1988.
Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
J. Virol.
62:2026-2032[Abstract/Free Full Text].
|
| 61.
|
Tersmette, M.,
J. M. Lange,
R. E. de Goede,
F. de Wolf,
J. K. Eeftink-Schattenkerk,
P. T. Schellekens,
R. A. Coutinho,
J. G. Huisman,
J. Goudsmit, and F. Miedema.
1989.
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.
Lancet
ii:983-985.
|
| 62.
|
Westervelt, P.,
D. Trowbridge,
L. Epstein,
B. Blumberg,
Y. Li,
B. Hahn,
G. Shaw,
R. Price, and L. Ratner.
1992.
Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.
J. Virol.
66:2577-2582[Abstract/Free Full Text].
|
| 63.
|
Wolinsky, S.,
B. Korber,
A. Neumann,
M. Daniels,
K. Kunstman,
A. Whetsell,
M. Furtado,
Y. Cao,
D. Ho,
J. Safrit, and R. Koup.
1996.
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.
Science
272:537-541[Abstract].
|
| 64.
|
Zhang, L.,
Y. Huang,
T. He,
Y. Cao, and D. Ho.
1996.
HIV-1 subtype and second-receptor usage.
Nature
383:768[Medline].
|